XTX Topco Ltd Invests $601,000 in Hims & Hers Health, Inc. (NYSE:HIMS)

XTX Topco Ltd purchased a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 24,836 shares of the company's stock, valued at approximately $601,000.

Several other institutional investors have also added to or reduced their stakes in HIMS. HighTower Advisors LLC bought a new stake in Hims & Hers Health in the third quarter valued at approximately $207,000. MML Investors Services LLC bought a new stake in shares of Hims & Hers Health in the 3rd quarter valued at $197,000. Barclays PLC lifted its position in shares of Hims & Hers Health by 9.7% during the 3rd quarter. Barclays PLC now owns 308,363 shares of the company's stock valued at $5,680,000 after acquiring an additional 27,231 shares during the period. Geode Capital Management LLC boosted its stake in Hims & Hers Health by 12.7% during the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company's stock worth $79,029,000 after acquiring an additional 482,177 shares in the last quarter. Finally, Sanctuary Advisors LLC grew its holdings in Hims & Hers Health by 26.8% in the third quarter. Sanctuary Advisors LLC now owns 26,057 shares of the company's stock worth $480,000 after purchasing an additional 5,505 shares during the period. 63.52% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Michael Chi sold 17,304 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $31.00, for a total value of $536,424.00. Following the transaction, the insider now owns 193,601 shares of the company's stock, valued at $6,001,631. This represents a 8.20 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Irene Becklund sold 2,936 shares of the firm's stock in a transaction dated Tuesday, April 22nd. The shares were sold at an average price of $26.49, for a total value of $77,774.64. Following the sale, the insider now owns 5,071 shares in the company, valued at $134,330.79. The trade was a 36.67 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 730,302 shares of company stock valued at $28,528,874. Company insiders own 17.71% of the company's stock.

Hims & Hers Health Stock Performance

HIMS traded up $1.71 during midday trading on Thursday, reaching $28.42. The company had a trading volume of 6,591,612 shares, compared to its average volume of 15,477,644. The stock has a market cap of $6.31 billion, a PE ratio of 64.49 and a beta of 1.65. Hims & Hers Health, Inc. has a 12-month low of $11.20 and a 12-month high of $72.98. The business has a 50-day moving average price of $35.50 and a two-hundred day moving average price of $30.78.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. The company had revenue of $481.14 million for the quarter, compared to analysts' expectations of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have commented on HIMS. Piper Sandler raised their price target on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a "neutral" rating in a report on Tuesday, February 25th. Leerink Partners raised their price target on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a report on Tuesday, February 25th. Citigroup restated a "sell" rating on shares of Hims & Hers Health in a report on Wednesday, April 2nd. Truist Financial reduced their price objective on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating for the company in a report on Thursday, April 10th. Finally, Canaccord Genuity Group lifted their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Hims & Hers Health presently has an average rating of "Hold" and an average price target of $38.25.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.